Cornelia Hain is an accomplished expert in device development and regulatory labeling, with over a decade of experience in the pharmaceutical and medical device industries. Currently Head of Device Development at Polpharma Biologics, she leads cross-functional teams in strategic planning, design control, and risk management for combination products. Her previous roles at Novartis and Sandoz included leadership in human factors engineering, labeling strategy, and regulatory compliance. Cornelia holds degrees in German language and linguistics from the University of Vienna and University College London.